
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Oculis Holding AG Ordinary shares (OCS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: OCS (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $37.55
1 Year Target Price $37.55
5 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.68% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 855.69M USD | Price to earnings Ratio - | 1Y Target Price 37.55 |
Price to earnings Ratio - | 1Y Target Price 37.55 | ||
Volume (30-day avg) 7 | Beta 0.12 | 52 Weeks Range 11.56 - 23.08 | Updated Date 08/29/2025 |
52 Weeks Range 11.56 - 23.08 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7957.09% |
Management Effectiveness
Return on Assets (TTM) -29.71% | Return on Equity (TTM) -83.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 657551736 | Price to Sales(TTM) 1120.01 |
Enterprise Value 657551736 | Price to Sales(TTM) 1120.01 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 52335800 | Shares Floating 40921330 |
Shares Outstanding 52335800 | Shares Floating 40921330 | ||
Percent Insiders 6.31 | Percent Institutions 31.11 |
Upturn AI SWOT
Oculis Holding AG Ordinary shares

Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company focused on developing innovative ophthalmic treatments. Founded in 2003, they have reached milestones in developing topical formulations to treat various eye diseases, shifting away from injected approaches.
Core Business Areas
- Dry Eye Disease: Developing licaminlimab (OCS-01), a topical antibody fragment, for the treatment of dry eye disease.
- Diabetic Macular Edema (DME): Developing OCS-02, a topical anti-TNFu03b1 antibody, for the treatment of DME.
- Neuro-retina: Developing OCS-05 for Neuro-retina indications such as optic neuritis.
Leadership and Structure
Riad Sherif is the Chief Executive Officer. The company operates with a management team overseeing research, clinical development, and commercial strategy. A board of directors provides governance and strategic oversight.
Top Products and Market Share
Key Offerings
- Licaminlimab (OCS-01): A topical antibody fragment being developed for Dry Eye Disease (DED). Market share is pre-launch, expected to compete with products like Xiidra and Restasis, and Miebo. Competitors: Novartis (Xiidra), AbbVie (Restasis), Bausch + Lomb (Miebo).
- OCS-02: A topical anti-TNFu03b1 antibody being developed for Diabetic Macular Edema (DME). Market share is pre-launch. Competitors: Regeneron (Eylea), Roche (Vabysmo), Novartis (Beovu).
- OCS-05: Under development for Neuro-retina applications such as optic neuritis. Market share is pre-launch. Competitors are limited due to novel approach. Treatment would be competing with steroids.
Market Dynamics
Industry Overview
The ophthalmic market is experiencing growth due to an aging population and increased prevalence of eye diseases. Innovation is focused on topical treatments and novel therapies.
Positioning
Oculis aims to disrupt the ophthalmic market with topical alternatives to injected therapies, potentially offering improved patient convenience and compliance.
Total Addressable Market (TAM)
The global ophthalmology market is estimated to be over $40 billion and growing. Oculis's positioning targets significant portions of this TAM with its lead products, especially in DED and DME.
Upturn SWOT Analysis
Strengths
- Novel topical formulations
- Potential for improved patient compliance
- Experienced management team
- Strong clinical pipeline
Weaknesses
- Dependence on clinical trial outcomes
- Pre-revenue company
- Competition from established players
- Manufacturing and regulatory risks
Opportunities
- Expansion into new ophthalmic indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Growing ophthalmic market
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from generics
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- NOVN (Novartis)
- ABBV (AbbVie)
- SNY (Sanofi)
- REGN (Regeneron)
- RHHBY (Roche)
Competitive Landscape
Oculis seeks to gain market share with topical medications competing with existing therapies, including injectables. They benefit from novel formulations but face competition from established players with strong market presence and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Focus is on clinical development and progressing through trial phases.
Future Projections: Growth is dependent on the successful commercialization of its lead drug candidates. Analyst estimates pending commercialization.
Recent Initiatives: Advancing OCS-01 and OCS-02 through Phase 3 trials, exploring new indications.
Summary
Oculis is a pre-revenue biopharmaceutical company with a promising pipeline of topical ophthalmic treatments. The company's success hinges on the outcomes of its late-stage clinical trials. It faces challenges from established competitors, however the topical delivery may present a paradigm shift in opthalmology, and has the potential to transform patient outcomes with new formulations. Key areas to monitor are clinical trial results, regulatory approvals, and market access strategies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Investor Presentations
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated. Investing in pharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://oculis.com |
Full time employees 49 | Website https://oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.